Redeye comments on Freemelt’s Q2 results, which marked a record quarter for the company, with revenu...
NoHo Partners reported Q2 EBIT of EUR 7.4m from continuing operations (down 11% y/y), 15% below Var...
Den tekniska utvärderingen av Prostatypes gentest fortsätter för att få produkten inkluderad i det a...
Ahead of Relais' Q2 results, we incorporate its latest acquisitions into our estimates and adjust fo...
H1e likely in line with guidance ONH is the growth engine, Sonans growth turns positive Fair value r...
Q2e: Clean paper EBIT of ~PLN 10m Challenging markets Fair value range of SEK 25-70 Q2e Paper EBIT ...
Ahead of Suominen's Q2 report, we maintain our estimates intact.
The combination of ELEVIDYS from Sarepta and Imlifidase records early supportive top-line data for p...
Delays weigh down the quarter’s results.
Solwers’ Board of Directors has today appointed Johan Ehrnrooth as Solwers’ upcoming CEO and he will...
BeammWave has formalised its long-standing collaboration with Nitto Denko through a Joint Developmen...
Redeye comments on the partnership with SD Pharma in Spain, which will broaden physician reach of Pe...
Redeye comments on today’s news from Thunderful Group, which includes a SEK50m directed share issue,...
The delayed launch is a setback for both XVIVO, patients and specialist centers waiting to use the s...
Market environment has remained slow Etteplan released a profit warning due to persistently weak ma...
